H1 2021 Results & Outlook
September 1st, 2021
P I O N E E R I N G D I A G N O S T I C S
DISCLAIMER
- This presentation contains information, assumptions and estimates that were used by the Company to determine its objectives on a reasonable basis. They are subject to change or modification due to economic, financial, medical and competitive uncertainties in markets addressed by bioMérieux. Further information regarding these assumptions, risks and estimates are described in the documents registered with the Autorité des Marchés Financiers.
- The forward-looking statements contained in this presentation apply only up to the date of the presentation. Accordingly, the Company cannot give any assurance as to whether it will achieve the objectives described in this presentation, and makes no commitment or undertaking to update or otherwise revise such information.
- This document does not constitute an offer to sell or an invitation or solicitation of an offer to subscribe for or purchase any securities, and this shall not form the basis for or be used for any such offer or invitation or other contract or engagement in any jurisdiction.
AGENDA
OVERVIEW of bioMérieux
H1 2021 ACTIVITY REVIEW
H1 2021 FINANCIAL RESULTS
2021 OUTLOOK
B I O M É R I E U X | 3 |
AT A GLANCE - 2020 FIGURES
- 55 YEARS OF EXPERTISE IN IN VITRO DIAGNOSTICS
CLINICAL | INDUSTRIAL |
APPLICATIONS | APPLICATIONS |
85% of revenues | 15% of revenues |
Sales amounting to | About 12,800 | 93% of | 1,900 people | Strong commitment |
€3.1 billion | employees worldwide | international sales | dedicated to R&D | to innovation 13% |
of sales invested in R&D
B I O M É R I E U X
MISSION, STRATEGY AND STRENGTHS
PIONEERING DIAGNOSTICS
To improve public health, focused
on the fight against infectious diseases
MICROBIOLOGY | MOLECULAR BIOLOGY |
Two leadership positions in both clinical | Leader in the syndromic diagnosis |
and industrial applications | of infectious diseases |
Broad & complementary range of | |
Wide & balanced geographic | |
footprint | solutions |
IMMUNOASSAYS
Specialized high medical value offer
Solid financial situation
B I O M É R I E U X
Pour lire la suite de ce noodl, vous pouvez consulter la version originale ici.
Attachments
- Original document
- Permalink
Disclaimer
BioMérieux SA published this content on 01 September 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 01 September 2021 19:31:10 UTC.